Ypsomed Holding AG · SIX:YPSN
Ypsomed — H1 2017/18 Earnings Presentation
32 slides from Ypsomed's earnings presentation, Nov 9, 2017
Slide 1: Half-year figures 2017/18
Half-year figures 2017/18 Zurich, 09 November 2017
Slide 2: Important information
Important information The information contained in this document has not been verified by an independent source. It should be taken with caution and no assurance or guarantee is given (either explicit or implied) with regard to the fairness, accuracy, completeness or correctness of the information o
Slide 3: Agenda
Agenda 1. Financial results 2. Ypsomed Diabetes Care 3. Ypsomed Delivery Systems 4. Ypsomed Group 5. Questions and answers 3 | Ypsomed Holding AG | Half-year figures 2017/18
Slide 4: Turnover increases by 15% during the 1st half-year
Turnover increases by 15% during the 1st half-year The Ypsomed Diabetes Care (YDC) segment grows with 25.2% to CHF 141.9 million. The share of the mylife™ OmniPod® amounts to CHF 79.9 million of turnover. The turnover in the Ypsomed Delivery Systems (YDS) segment for the first half-year is sligh
Slide 5: Results on track for the first half-year 2017/18
Results on track for the first half-year 2017/18 Due to consistently continued, growth-oriented activities, the EBIT at CHF 26.9 million remains slightly under the previous year's level of CHF 28.1 million. Market introduction programmes and increased amortisation for the development of the myli
Slide 6: The earnings per share increase by 4.5% to CHF 1.86
The earnings per share increase by 4.5% to CHF 1.86 6 | Ypsomed Holding AG | Half-year figures 2017/18
Slide 7: Growth investments increase to CHF 26 million
Increase in strategic investments by CHF 9 million Growth investments increase to CHF 26 million (previous year: CHF 17 million) – New building laboratory, technical centre, office workplaces (CH) – Expansion production capacities (CH) – New building production capacities (DE) – Further developmen
Slide 8: The cash holdings assure further investments
The cash holdings assure further investments 8 | Ypsomed Holding AG | Half-year figures 2017/18
Slide 9: Solid equity ratio
Solid equity ratio 9 | Ypsomed Holding AG | Half-year figures 2017/18
Slide 10: Outlook for the business year 2017/18 is raised
Outlook for the business year 2017/18 is raised We will increase the outlook for growth in turnover from 15% to 18% compared with the previous year. We expect an EBIT of around CHF 60 million. Ypsomed's existing dividend policy remains unchanged. 10 | Ypsomed Holding AG | Half-year figures 201
Slide 11: Ypsomed Business Segments
Ypsomed Business Segments 11 | Ypsomed Holding AG | Half-year figures 2017/18
Slide 12: Ypsomed Diabetes Care
Ypsomed Diabetes Care 12 | Ypsomed Holding AG | Half-year figures 2017/18
Slide 13: Separation from Insulet Corp.
Separation from Insulet Corp. Insulet Corp. and Ypsomed have decided not to extend the distribution agreement. Until 30 June 2018, Ypsomed will continue to supply European mylife™ OmniPod® customers reliably. For the financial year 2017/18 we expect a revenue contribution of CHF 165 million an
Slide 14: Focus on own manufactured products
Focus on own manufactured products Ypsomed covers the entire value creation chain for the most important products in the mylife™ Diabetescare portfolio integrally. This will increase profitability considerably in the mid-term. Furthermore, we have the full flexibility in technical further develo
Slide 15: Solid start of the new mylife YpsoPump
Solid start of the new mylife™ YpsoPump® The own manufactured mylife™ YpsoPump® insulin pump will soon be available in 10 countries. Customer and HCP satisfaction remains high throughout and confirms the need for an easy-to-use system. The insulin pump is distinguished by its robustness and re
Slide 16: Clearly defined development plan
Clearly defined development plan Integration of sensor data of continuous blood glucose metering systems Control app for insulin pumps SmartLoop™ functionalities Further development of digital therapeutic support Expansion of digital services Patch pump mylife™ YpsoPod® 16 | Ypsomed Hold
Slide 17: Reshoring the production of the Orbit infusion set
Reshoring the production of the Orbit® infusion set Extension of manual production in Mexico and establishment of a highly automated production plant in Solothurn with an annual capacity of 2 million units (2017). Followed by expansion in Schwerin with an annual capacity of 10 million units (201
Slide 18: Ypsomed supplies Bigfoot Biomedical with Orbit infusion set
Ypsomed supplies Bigfoot Biomedical with Orbit® infusion set for the clinical study of their system 18 | Ypsomed Holding AG | Half-year figures 2017/18
Slide 19: Expansion of market access is continued
Expansion of market access is continued The market potential continues to grow, but some market participants are pulling out (Animas Corporation). With its mylife™ Diabetescare brand, Ypsomed Diabetes Care is well established as a trustworthy and reliable supplier in Europe. For 2018, we plan
Slide 20: Ypsomed Delivery Systems
Ypsomed Delivery Systems 20 | Ypsomed Holding AG | Half-year figures 2017/18
Slide 21: Strategic cornerstones
Strategic cornerstones Favourable time window Platforms Diabetes is a global pandemic. Reduction of risks due to proven Patent cliff as an opportunity for new platform and thus shortened "time-to- pharmaceutical companies and global market". expansion of access to medicinal “Piece of mind” d
Slide 22: Overview of indications and current platforms
Overview of indications and current platforms Indications Indications Diabetes (insulin, GLP-1) Autoimmune disorders Growth disorders Migraine Fertility Multiple sclerosis Immuno-oncology Platform family pens Platform family autoinjectors 22 | Ypsomed Holding AG | Half-year figures 201
Slide 23: Current developments
Current developments 23 | Ypsomed Holding AG | Half-year figures 2017/18
Slide 24: Order pipeline
Order pipeline 24 | Ypsomed Holding AG | Half-year figures 2017/18
Slide 25: Order pipeline and its effect on turnover
Order pipeline and its effect on turnover 25 | Ypsomed Holding AG | Half-year figures 2017/18
Slide 26: Massive expansion of production capacities
Massive expansion of production capacities We continuously expand the production capacities for our platforms corresponding to our pipeline: By 2019/20: full expansion of our capacities at the Swiss sites From 2019/20: commissioning of the production lines for pens and autoinjectors in Schwerin
Slide 27: Expansion at Burgdorf headquarters
Expansion at Burgdorf headquarters Doubling and modernisation of tool manufacturing and laboratory. Installation of a technical centre for faster and centralised validation of new tools. Creation of an additional 80 office workplaces. Expansion of the central site allows perfect cooperation
Slide 28: Ypsomed creates more than 100 jobs in Switzerland
Ypsomed creates more than 100 jobs in Switzerland 28 | Ypsomed Holding AG | Half-year figures 2017/18
Slide 29: Ypsomed's strategic cornerstones remain unchanged
Ypsomed's strategic cornerstones remain unchanged Ypsomed is oriented towards long- term profitability. We invest unchanged on the basis of a healthy and solid balance in – maintaining technological leadership – maintaining cost leadership – expanding our production capacities – extending our ma
Slide 30: Outlook Ypsomed for 2020/21
Outlook Ypsomed for 2020/21 Compensation of decrease in turnover With an increase in profitability due to loss of mylife™ Omnipod® Development of turnover including special effect of the Development of the EBIT including special effect of the compensation payment by Insulet Corp. compensation paymen
Slide 31: Key upcoming dates
Key upcoming dates Presentation Financial Figures 2017/18 24 May 2018 in Burgdorf General Assembly of Shareholders 27 June 2018 in Burgdorf 31 | Ypsomed Holding AG | Half-year figures 2017/18
Slide 32: Questions and answers
Questions and answers